<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00641563</url>
  </required_header>
  <id_info>
    <org_study_id>KIM-NMP3</org_study_id>
    <nct_id>NCT00641563</nct_id>
  </id_info>
  <brief_title>Effects of Two Different Sedation Regimes on Auditory Evoked Potentials and Electroencephalogram (EEG)</brief_title>
  <official_title>The Effects of Dexmedetomidine/Remifentanil and Midazolam/Remifentanil on Auditory-evoked Potentials and Electroencephalogram at Light-to-moderate Sedation Levels in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sedation may be necessary in intensive care to facilitate diverse therapeutic interventions,
      but the use of sedative drugs may increase the risk of delirium and long-term cognitive
      impairment. Thus the implementation and monitoring of sedation remains difficult despite the
      use of sedation protocols and clinical sedation scores. Attempts to improve sedation
      monitoring through the use of the electroencephalogram(EEG) have been disappointing. Derived
      variables based on the unstimulated EEG fail to predict the response to external stimuli at
      the clinically most relevant light-to-moderate sedation levels, and the overlap between
      moderate and deep sedation levels is wide. We have demonstrated that long-latency auditory
      evoked potentials (ERPs)can be used to avoid deep levels of sedation in healthy volunteers
      during propofol sedation, independent of the concomitant administration of remifentanil. This
      approach has a potential clinical application for improved monitoring of sedation. Since the
      effects of different sedative drugs on the EEG may vary widely, the use of ERPs to monitor
      sedation needs to be evaluated with different sedative drugs. Therefore we will administer
      two widely used drug combinations (dexmedetomidine/remifentanil and midazolam/remifentanil)
      in healthy volunteers and record ERPS and processed EEG during clinical relevant sedation
      levels
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sedation may be necessary in intensive care to facilitate diverse therapeutic interventions,
      but the use of sedative drugs may increase the risk of delirium and long-term cognitive
      impairment. Thus the implementation and monitoring of sedation remains difficult despite the
      use of sedation protocols and clinical sedation scores. Attempts to improve sedation
      monitoring through the use of the electroencephalogram (EEG) have been disappointing. Derived
      variables based on the unstimulated EEG fail to predict the response to external stimuli at
      the clinically most relevant light-to-moderate sedation levels, and the overlap between
      moderate and deep sedation levels is wide. We have demonstrated that long-latency auditory
      evoked potentials (ERPs)can be used to avoid deep levels of sedation in healthy volunteers
      during propofol sedation, independent of the concomitant administration of remifentanil. This
      approach has a potential clinical application for improved monitoring of sedation. Since the
      effects of different sedative drugs on the EEG may vary widely, the use of ERPs to monitor
      sedation needs to be evaluated with different sedative drugs. The alpha-2 agonist
      dexmedetomidine (dex) has been approved for short-term sedation in surgical intensive care
      unit (ICU) patients. Preliminary data suggest that the risk of delirium may be substantially
      reduced when dexmedetomidine is used to produce sedation. Since dexmedetomidine acts via
      different receptors and brain areas than do benzodiazepines and propofol, its impact on the
      brain electrophysiology may also be different. The assessment of dexmedetomidine's effects on
      the EEG and ERPs at various sedation levels has been limited in humans. We hypothesized that
      the combinations DEXMEDETOMIDINE/REMIFANTANIL (dex/remi) and MIDAZOLAM/REMIFENTANIL
      (mida/remi) would induce the same changes in EEG and long-latency ERPs during
      light-to-moderate levels of sedation in healthy subjects, despite the different quality of
      sedation that they provide. The opioid remifentanil was added because virtually all patients
      in the ICU have some level of pain and receive an opioid analgesic in combination with a
      sedative. 10 healthy subjects were assessed with both drug combinations (dex/remi and
      mida/remi), at least 7 days apart. The sequence of the drug combinations were randomized.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amplitudes (in Micro Volts) of Acoustic Event Related Potentials (Time-locked Amplitudes in the Electroencephalogram 100 Milliseconds After the Acoustic Stimulus, Averaged Over 40 Stimuli)Awake and at 3 Different Drug-induced Sedation Levels</measure>
    <time_frame>awake + 3 sedation levels (RS2/3/4) (20 minutes each)</time_frame>
    <description>Event Related Potentials (time-locked amplitudes in the electroencephalogram 100 milliseconds after the acoustic stimulus, averaged over 40 stimuli) Sedation levels were graded with the Ramsay scale (RS), where the responses of patients to standardized increasing stimuli (voice, then prodding, the pain stimulus) are graded. The higher the number, the deeper is the sedation. RS 6 means no response at all (= anesthesia)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BIS-Index Awake and 3 Sedation Levels (RS 2/3/4)</measure>
    <time_frame>awake and 3 sedation levels (RS 2/3/4) 20 min each</time_frame>
    <description>BIS-Index is a dimensionless value ranging from 0-100, indicating fully awake at 100 and a flat-line electroencephalogram at 0. Standard anesthesia creates a BIS-Index range 40-60. The scale is ordinal, not interval. BIS Index is calculated from the EEG by a proprietary algorithm (Aspect Medical Inc.)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Conscious Sedation</condition>
  <condition>Deep Sedation</condition>
  <condition>Critical Care</condition>
  <arm_group>
    <arm_group_label>Dex/Remi followed by Mida/Remi</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sedation with dexmedetomidine and remifentanil followed by sedation with midazolam and remifentanil separated by one week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mida/Remi followed by Dexa/Remi</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sedation with midazolam and remifentanil followed by sedation with dexmedetomidine and remifentanil separated by one week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Infusion of dexmedetomidine</description>
    <arm_group_label>Dex/Remi followed by Mida/Remi</arm_group_label>
    <arm_group_label>Mida/Remi followed by Dexa/Remi</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam infusion</description>
    <arm_group_label>Dex/Remi followed by Mida/Remi</arm_group_label>
    <arm_group_label>Mida/Remi followed by Dexa/Remi</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Infusion of remifentanil</description>
    <arm_group_label>Dex/Remi followed by Mida/Remi</arm_group_label>
    <arm_group_label>Mida/Remi followed by Dexa/Remi</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 years and older

          -  healthy

        Exclusion Criteria:

          -  History of problems during anesthesia

          -  Impairment of the auditory system
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Haenggi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departement of Intensive Care Medicine - University Hospital Bern - Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Haenggi M, Ypparila H, Takala J, Korhonen I, Luginbühl M, Petersen-Felix S, Jakob SM. Measuring depth of sedation with auditory evoked potentials during controlled infusion of propofol and remifentanil in healthy volunteers. Anesth Analg. 2004 Dec;99(6):1728-36, table of contents.</citation>
    <PMID>15562062</PMID>
  </reference>
  <results_reference>
    <citation>Haenggi M, Ypparila H, Hauser K, Caviezel C, Korhonen I, Takala J, Jakob SM. The effects of dexmedetomidine/remifentanil and midazolam/remifentanil on auditory-evoked potentials and electroencephalogram at light-to-moderate sedation levels in healthy subjects. Anesth Analg. 2006 Nov;103(5):1163-9.</citation>
    <PMID>17056949</PMID>
  </results_reference>
  <results_reference>
    <citation>Haenggi M, Ypparila-Wolters H, Hauser K, Caviezel C, Takala J, Korhonen I, Jakob SM. Intra- and inter-individual variation of BIS-index and Entropy during controlled sedation with midazolam/remifentanil and dexmedetomidine/remifentanil in healthy volunteers: an interventional study. Crit Care. 2009;13(1):R20. doi: 10.1186/cc7723. Epub 2009 Feb 19.</citation>
    <PMID>19228415</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2008</study_first_posted>
  <results_first_submitted>April 27, 2009</results_first_submitted>
  <results_first_submitted_qc>October 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 22, 2011</results_first_posted>
  <last_update_submitted>October 13, 2011</last_update_submitted>
  <last_update_submitted_qc>October 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Matthias Haenggi</name_title>
    <organization>Department of Intensive Care Medicine, university Hospital Bern - Inselspital</organization>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>midazolam</keyword>
  <keyword>remifentanil</keyword>
  <keyword>Electroencephalography</keyword>
  <keyword>Event related potentials</keyword>
  <keyword>BIS</keyword>
  <keyword>Bispectral Index</keyword>
  <keyword>Response Entropy</keyword>
  <keyword>State Entropy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dex/Remi Followed by Mida/Remi</title>
          <description>Sedation with dexmedetomidine and remifentanil followed by sedation with midazolam and remifentanil separated by one week</description>
        </group>
        <group group_id="P2">
          <title>Mida/Remi Followed by Dex/Remi</title>
          <description>Sedation with midazolam and remifentanil followed by sedation with dexmedetomidine and remifentanil separated by one week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Infusion 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Infusion 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Both arms combined</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Amplitudes (in Micro Volts) of Acoustic Event Related Potentials (Time-locked Amplitudes in the Electroencephalogram 100 Milliseconds After the Acoustic Stimulus, Averaged Over 40 Stimuli)Awake and at 3 Different Drug-induced Sedation Levels</title>
        <description>Event Related Potentials (time-locked amplitudes in the electroencephalogram 100 milliseconds after the acoustic stimulus, averaged over 40 stimuli) Sedation levels were graded with the Ramsay scale (RS), where the responses of patients to standardized increasing stimuli (voice, then prodding, the pain stimulus) are graded. The higher the number, the deeper is the sedation. RS 6 means no response at all (= anesthesia)</description>
        <time_frame>awake + 3 sedation levels (RS2/3/4) (20 minutes each)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dex/Remi</title>
            <description>Sedation with dexmedetomidine and remifentanil</description>
          </group>
          <group group_id="O2">
            <title>Mida/Remi</title>
            <description>Sedation with midazolam and remifentanil</description>
          </group>
        </group_list>
        <measure>
          <title>Amplitudes (in Micro Volts) of Acoustic Event Related Potentials (Time-locked Amplitudes in the Electroencephalogram 100 Milliseconds After the Acoustic Stimulus, Averaged Over 40 Stimuli)Awake and at 3 Different Drug-induced Sedation Levels</title>
          <description>Event Related Potentials (time-locked amplitudes in the electroencephalogram 100 milliseconds after the acoustic stimulus, averaged over 40 stimuli) Sedation levels were graded with the Ramsay scale (RS), where the responses of patients to standardized increasing stimuli (voice, then prodding, the pain stimulus) are graded. The higher the number, the deeper is the sedation. RS 6 means no response at all (= anesthesia)</description>
          <units>micro Volt</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>awake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="1.3"/>
                    <measurement group_id="O2" value="-5.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RS 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="1.1"/>
                    <measurement group_id="O2" value="-4.8" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RS 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="2.4"/>
                    <measurement group_id="O2" value="-2.4" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RS 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="2.7"/>
                    <measurement group_id="O2" value="-0.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BIS-Index Awake and 3 Sedation Levels (RS 2/3/4)</title>
        <description>BIS-Index is a dimensionless value ranging from 0-100, indicating fully awake at 100 and a flat-line electroencephalogram at 0. Standard anesthesia creates a BIS-Index range 40-60. The scale is ordinal, not interval. BIS Index is calculated from the EEG by a proprietary algorithm (Aspect Medical Inc.)</description>
        <time_frame>awake and 3 sedation levels (RS 2/3/4) 20 min each</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dex/Remi</title>
            <description>Sedation with dexmedetomidine and remifentanil</description>
          </group>
          <group group_id="O2">
            <title>Mida/Remi</title>
            <description>Sedation with midazolam and remifentanil</description>
          </group>
        </group_list>
        <measure>
          <title>BIS-Index Awake and 3 Sedation Levels (RS 2/3/4)</title>
          <description>BIS-Index is a dimensionless value ranging from 0-100, indicating fully awake at 100 and a flat-line electroencephalogram at 0. Standard anesthesia creates a BIS-Index range 40-60. The scale is ordinal, not interval. BIS Index is calculated from the EEG by a proprietary algorithm (Aspect Medical Inc.)</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>awake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" spread="4.64"/>
                    <measurement group_id="O2" value="93.7" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sedation level RS 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5" spread="5.82"/>
                    <measurement group_id="O2" value="84.7" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sedation level RS 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5" spread="8.05"/>
                    <measurement group_id="O2" value="73.2" spread="6.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sedation level RS 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" spread="7.16"/>
                    <measurement group_id="O2" value="68.9" spread="5.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dex/Remi</title>
          <description>Sedation with dexmedetomidine and remifentanil</description>
        </group>
        <group group_id="E2">
          <title>Mida/Remi Followed by Dex/Remi</title>
          <description>Sedation with midazolam and remifentanil followed by sedation with dexmedetomidine and remifentanil separated by one week</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. M. Hänggi</name_or_title>
      <organization>University Hospital Bern, Switzerland</organization>
      <phone>0316323029</phone>
      <email>matthias.haenggi@insel.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

